Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

NASH is becoming a leading indication for liver transplants in patients with hepatocellular carcinoma

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the USA, reports this month's issue of Hepatology.

News image

Nonalcoholic steatohepatitis (NASH) is currently the third leading indication for liver transplantation in the U.S. and is predicted to become the leading indication for liver transplantation in the near future.

The trends in NASH-related hepatocellular carcinoma (HCC) among liver transplantation recipients in the U.S. remain undefined.

Dr Aijaz Ahmed and colleagues from California, USA performed a retrospective cohort study to evaluate trends in the etiology of HCC among adult liver transplantation recipients in the U.S. from 2002 to 2012, using national data from the United Network for Organ Sharing registry.

From 2002-2012, there were 61,868 adults who underwent liver transplantation in the U.S., including 10,061 patients with HCC.

NASH is the second leading etiology of HCC-related liver transplantation
Hepatology

The team noted that the total number and proportion of HCC liver transplant recipients demonstrated a significant increase following the implementation of the Model for Endstage Liver Disease (MELD) scoring system in 2002.

The researchers observed that the proportion of hepatitis C virus (HCV)-related HCC increased steadily from 2002 to 2012, and HCV remained the leading etiology of HCC throughout the MELD era.

The team found that NASH-related HCC also increased significantly, and NASH is the second leading etiology of HCC-related liver transplantation.

From 2002 to 2012, the number of patients undergoing liver transplantation for HCC secondary to NASH increased by nearly 4-fold, and the number of liver transplantation patients with HCC secondary to HCV increased by 2-fold.

Dr Ahmed's team comments, "NASH is the second leading etiology of HCC leading to liver transplantation in the U.S."

"More important, NASH is currently the most rapidly growing indication for liver transplantation in patients with HCC in the U.S."

Hepatology 2014: 59(6): 2188–2195
17 June 2014

Go to top of page Email this page Email this page to a colleague

 27 November 2014

Advanced search
 27 November 2014 
Prediction of functional GI disorders later in life
 27 November 2014 
Differences in the incidence of esophageal adenocarcinoma
 27 November 2014 
End points of outcomes in primary biliary cirrhosis
 26 November 2014 
Detection of gastric precancerous conditions
 26 November 2014 
Vegetables and garlic and colorectal cancer risk
 26 November 2014 
Fertility in women with celiac disease
 25 November 2014 
Esophagogastric junction of children with GERD
 25 November 2014 
Symptom activity index for eosinophilic esophagitis
 25 November 2014 
Placebo response rate in fistulizing Crohn's
 24 November 2014 
Nasoenteric tube feeding in acute pancreatitis
 24 November 2014 
Corticosteroids and infections in elderly-onset IBD
 24 November 2014 
Adhesions in abdominal and pelvic surgery
 21 November 2014 
Hepatic involvement in IgG4-related disease
 21 November 2014 
Skin cancer in ulcerative colitis patients
 21 November 2014 
Mortality of chemoembolization in hepatocellular carcinoma
 20 November 2014 
Global measures in chronic idiopathic constipation
 20 November 2014 
Macrophage activation in alcoholic hepatitis
 20 November 2014 
Covert hepatic encephalopathy and survival
 19 November 2014 
Thiopurine withdrawal in IBD
 19 November 2014 
Esophageal narrowing in esophageal eosinophilia
 19 November 2014 
Second intestinal resection in Crohn's
 18 November 2014 
Colorectal neoplasia and vitamin D
 18 November 2014 
Food-associated changes in the intestinal mucosa in IBS
 18 November 2014 
Alternative medicine use by US adults
 17 November 2014 
Allergy-related diseases and abdominal pain in childhood
 17 November 2014 
Treatment of obesity in primary care settings
 17 November 2014 
Diagnosis of monogenic very early onset IBD
 14 November 2014 
Second intestinal resection in Crohn's
 14 November 2014 
HCC risk in active stage Hep B
 14 November 2014 
Thiopurine and clinical remission in IBD
 13 November 2014 
Antibiotics and risk of new-onset Crohn’s
 13 November 2014 
Chronic Hep C genotype 1 treatment after relapse
 13 November 2014 
Chemoembolization for hepatocellular carcinoma
 12 November 2014 
Risk of hepatocellular carcinoma
 12 November 2014 
Abdominal symptom severity in chronic idiopathic constipation
 12 November 2014 
Screening colonoscopy
 11 November 2014 
Hepatocellular carcinoma in Hep B with nucleotide analogue
 11 November 2014 
Familial colorectal cancer screening
 11 November 2014 
Fecal microbiota transplant for C. diff
 10 November 2014 
STaples IPAA for ulcerative colitis
 10 November 2014 
Blood stream infections in acute liver failure
 10 November 2014 
Ig4-related disease
 07 November 2014 
Host and viral factors in chronic Hep C
 07 November 2014 
Celiac diagnosis without biopsy
 07 November 2014 
Pricing practices of gastroenterologists
 06 November 2014 

Colorectal surgery postdischarge occurrences and readmissions

 06 November 2014 
Thromboprophylaxis in IBD
 06 November 2014 
Steatosis biomarkers in NAFLD
 05 November 2014 
Readmission risk factors for patients with IBD
 05 November 2014 
Hysterectomy and colonoscopy completion
 05 November 2014 
Adalimumab in Crohn's disease
 04 November 2014 
Gut barrier dysfunction and CNS disorders
 04 November 2014 
Hemospray for nonvariceal upper GI bleeding
 04 November 2014 
Sleep duration and ulcerative colitis
 03 November 2014 
Mucosal pathophysiology in HIV and IBD
 03 November 2014 
Managing bleeding gastroduodenal ulcers
 03 November 2014 
Identifying inflammation in ulcerative colitis
 31 October 2014 
Pregnancy complications in celiac disease
 31 October 2014 
Pediatric NAFLD
 31 October 2014 
C. difficile infection with metronidazole

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us